ITOCD Event 2010


Targeting Tumor Angiogenesis: Molecular Biology and Clinical Practice

Chairs: R. Herrmann, Basel / N. Saijo, Tokyo


Biomarkers profile and clinical factors in selecting patients

A.B. Sandler, Portland

Presentation PDF


Imaging in targeted therapy

C. Fink, Mannheim

Presentation PDF


Management of toxicity of anti-angiogenic/anti-EGFR agents

J. Heymach, Houston

Presentation PDF


Integrin inhibitors

S. Peters, Lausanne

Presentation PDF


Vascular disrupting agents

J.Y. Doulliard, Nantes

Presentation PDF


Anti-angiogenic TKI’s

U. Gatzemeier, Großhansdorf

Presentation PDF


Molecular biology

E. Voest, Utrecht


Novel Agents I

Chairs: W. Eberhardt, Essen / T. Le Chevalier, Paris


Heat shock protein targeting agents

K. O’Byrne, Dublin

Presentation PDF


Histone deacetylase inhibitors

S. Ramalingam, Atlanta

Presentation PDF



J.-C. Soria, Paris

Presentation PDF


Dendritic cell recruitors and activators

A. Y. Chang, Singapore

Presentation PDF


Vaccine therapy

J. Vansteenkiste, Leuven

Presentation PDF


Pro-apoptotic agents

F. R. Khuri, Atlanta

Presentation PDF


Mannheim Lilly Oncology Lecture


Targeted therapy: how to clinically develop new agents and treatment strategies based on pre-clinical information

P. Bunn, Denver

Presentation PDF


Targeting the Epidermal Growth Factor Receptor (EGFR): Molecular Biology and Clinical Practice

Chairs: N.Thatcher, Manchester / K. Syrigos, Athens


Molecular biology of the EGFR-pathway

A. F. Gazdar, Dallas

Presentation PDF


Clinical and molecular predictors of EGFR-TKI sensitivity

F. A. Shepherd, Toronto

Presentation PDF


Mechanism of drug resistance and how to overcome first generation EGFR- TKI failure

P. A. Jänne, Boston

Presentation PDF


EGFR-TKI first-line therapy: diagnostic assessment and drug selection

T. Mok, Hong Kong

Presentation PDF


EGFR-assessment in prospective clinical trials

R. Dziadziusko, Gdansk

Presentation PDF


Treatment duration and sequencing of EGFR-TKI inhibitors

F. Cappuzzo, Livorno

Presentation PDF


EGFR-targeting antibodies: clinical and molecular sensitivity predictors

R. Pirker, Vienna

Presentation PDF


EGFR-targeting antibodies in combination with radiotherapy

F. Mornex, Lyon

Presentation PDF


NSCLC: Relevance of Treatment Prediction by Histology for Early and Advanced Disease

Chairs: F. Blackhall, Manchester / C. Manegold, Mannheim


Relevance of TS testing: British experience

K. Kerr, Aberdeen

Presentation PDF


Pharmacogenomic guided treatment strategies for early NSCLC

G. V. Scagliotti, Torino

Presentation PDF


Pemetrexed (Alimta therapy): duration and frequency

C. Belani, Hersey

Presentation PDF


Gene Expression/Tumor Histology Guided Therapy

Chairs: N. van Zandwijk, Sydney / J. Niklinski, Bialystok


Molecular basis

H. Allgayer, Mannheim

Presentation PDF


Proteomics and outcome prediction

D. P. Carbone, Nashville


Rationale for Genomic Guided Molecular Therapy in Lung Cancer

A. Potti, Durham / N. Ready, Durham

Presentation PDF


MicroRNA signatures and outcome prediction

P.-C. Yang, Taiwan

Presentation PDF


TS-expression and sensitivity to anti-folates

G. V. Scagliotti, Torino

Presentation PDF


ERCC1, RRM1, and BRCA1-gene expression and outcome prediction

G. Bepler, Detroit

Presentation PDF


Tumor histology and clinical outcome

C. Manegold, Mannheim

Presentation PDF


Novel Agents II

Chairs: P. Postmus, Amsterdam / J. S. Lee, Seoul


ACT, MAPK, MEK-inhibitors

A. Adjei, Buffalo

Presentation PDF


ALK, MET-inhibitors

R. Stahel, Zürich

Presentation PDF


SRC-targeting agents

O. Gautschi, Bern

Presentation PDF



L. Crinò, Perugia

Presentation PDF


Insulin growth factor receptor targeting agents

L. Paz-Ares, Sevilla

Presentation PDF


Tabacco Control and Lung Cancer Prevention

(supported by an Eli-Lilly unrestricted educational grant)

Chairs: L.R. Pilz, Heidelberg / K. Park, Seoul


WHO perspectives in reducing lung cancer mortality

A. Ullrich, Geneva

Presentation PDF


Tobacco control policy in Poland

J. Jassem, Gdansk

Presentation PDF


Smoking cessation in women

C. M. Dresler, Littler Rock

Presentation PDF


Female gender as a prognostic and predictive factor

S. Novello, Torino

Presentation PDF


New targets for chemoprevention

Y. E. Miller, Denver

Presentation PDF


Chemoprevention of high risk patient populations

N. van Zandwijk, Sydney

Presentation PDF


2010 Challenges in Thoracic Oncology I

Chairs: D. H. Grunenwald, Paris / C. Zhou, Shanghai


Implications of the new TNM system for the surgical management of early stage lung cancer

P. Goldstraw, London

Presentation PDF


Implications of the new TNM system for modern imaging

S. Schönberg, Mannheim / C. Fink, Mannheim

Presentation PDF


Minimally invasive non-surgical methods for staging lung cancer

F. Herth, Heidelberg

Presentation PDF


Adjuvant chemotherapy

B. Besse, Paris

Presentation PDF


Induction chemotherapy

P. van Schil, Antwerp

Presentation PDF


Advanced NSCLC: maintenance therapy

C. Belani, Hersey

Presentation PDF


2010 Challenges in Thoracic Oncology II

Chairs: P. Hohenberger, Mannheim / E. Smit, Amsterdam


Stereotactic radiation therapy for stage I NSCLC

F. Wenz, Mannheim

Presentation PDF



D. de Ruysscher, Maastricht

Presentation PDF


Is thymic carcinoma a specific entity?

A. Marx, Mannheim / P. Ströbel, Mannheim

Presentation PDF


Malignant pleural mesothelioma: extension of surgery

W. Weder, Zurich

Presentation PDF


Malignant pleural mesothelioma: new drug development

D. Fennell, Belfast

Presentation PDF


SCLC: Combined modality therapy in limited stage disease

A. Ardizzoni, Parma

Presentation PDF



About us

PEKKIP Congress GmbH is responsible for planning, executing and following up high-class medical conventions, training courses, advisory boards and networking events.

A brief history overview

Did you miss one of our events or would like to review some of the information from past conventions? It doesn’t get easier than this. Simply read through all the details here.

There’s always someone around to serve you. 

Do you have questions about our offers or need more information on one of our events? Give us a ring on +49 (0)6221 655 700, and we will be happy to help you.

Additional ways to contact us